Pure platelet-rich plasma represents 42.0% of composition type demand and autologous PRP accounts for 86.0% of source sales in 2026. The platelet rich plasma market was valued at USD 0.5 billion in 2025 and is projected to reach USD 1.4 billion by 2036, creating an incremental opportunity of USD 0.9 billion.